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MinireviewBranches of the B Cell Antigen
Receptor Pathway Are Directed by
Protein Conduits Bam32 and Carma1
1999; Marshall et al., 2000; Rao et al., 1999) (Figure 1).
It is 32 kDa in size and has an N-terminal src-homology
2 (SH2) domain and a novel pleckstrin homology (PH)
domain with a very high affinity for PI(3,4,5)P3 and
PI(3,4)P2. This affinity of Bam32 is much higher than that
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of other well-known PH-containing molecules such as
PDK1 and Btk (Dowler et al., 1999). In addition, Bam32
has one tyrosine phosphorylation site (Y139), which is
Adaptor proteins act as conduits to channel upstream phosphorylated upon BCR crosslinking. After BCR liga-
signals into downstream effector branches. Two B tion, Bam32 is recruited to the plasma membrane via
cell-associated adaptors, Bam32 and Carma1, regu- its PH domain and induced to associate with PLC2 via
late the ERK, JNK, and NF-B branches of the BCR its SH2 domain (Marshall et al., 2000).signaling pathway. Recent studies of Bam32/ and A first clue into the role of Bam32 in BCR signaling
Carma1/ mice suggest that each adaptor controls came from studies of Bam32/ DT40 cells (Niiro et al.,
a distinct conduit regulating either only proliferation
2002). Bam32/ DT40 cells were more susceptible to
(Bam32) or both the proliferation and survival of B
BCR-induced apoptosis and in particular did not acti-
cells (Carma1).
vate c-jun N-terminal kinase (JNK) after BCR crosslink-
ing. They also had partial defects in BCR-induced Ca2
influx, activation of extracellular signal-regulated kinaseIntroduction
(ERK), p38 mitogen-activated protein kinase (MAPK),B cell antigen receptor (BCR) signals are crucial for B
nuclear factor of activated T cells (NF-AT), and nuclearcell fate decisions at several developmental checkpoints
factor of  binding (NF-B).(Niiro and Clark, 2002). In immature B cells BCR signals
B Cell Development and Immune Responsestriggered by self-antigens can lead to either deletion
in Bam32/ Mice(apoptosis), inactivation (anergy), or receptor editing,
Two groups recently generated Bam32-deficient micewhile BCR ligation in mature B cells initiates signaling
using a conventional germline knockout technique andpathways that confer B cell survival, proliferation, and
a viral gene trap approach, respectively (Fournier et al.,differentiation. In addition, the presence of a functional
2003; Han et al., 2003). Consistent with the findings inBCR on the cell surface is required for B cells to survive
humans (Marshall et al., 2000), mouse Bam32 expres-(Lam et al., 1997).
sion is mainly restricted to hematopoietic tissues (HanThe most proximal BCR signaling point involves acti-
vation of protein tyrosine kinases (PTKs) (e.g., Lyn, Syk, et al., 2003). Did disruption of Bam32 affect B cell devel-
Btk/Tec) and then serine/threonine kinases (e.g., PKC, opment? Both groups found that Bam32/ mice have
Akt) and phosphoinositide kinases (e.g., PI3 kinase). relatively normal development of both B cells and T cells
Thus, knockouts of these kinases cause defects in B and have normal numbers of T1, T2, follicular (FO), and
cell activation and development (Niiro and Clark, 2002). marginal zone (MZ) B cells in the spleen. However, Han
In addition to these kinases, B cell adaptors function et al. found that the proportion of peritoneal B-1a cells
as molecular conduits to effectively channel upstream is clearly decreased in Bam32/ mice, while Fournier
signals to specific downstream branches (Niiro and et al. did not. Since a number of studies suggest that
Clark, 2002). For instance, B cell development in B cell strong BCR signaling is required for B-1a cell generation
linker (BLNK)-deficient mice is blocked at the transition (Niiro and Clark, 2002), the results of Han and coworkers
from pro-B to pre-B cells in the bone marrow (Jumaa suggest that BCR signaling is attenuated in Bam32/
et al., 1999). B cell development in BLNK/ mice is also B cells.
blocked at the type 2 transitional (T2) B cell stage in the Peritoneal B-1a cells play a pivotal role in T cell-inde-
spleen (Jumaa et al., 1999). BLNK/ B cells in vitro pendent immune responses (Berland and Wortis, 2002).
exhibit impaired cell survival and proliferation and Consistent with this, both groups found that T cell-inde-
greatly diminished Ca2 release upon BCR crosslinking pendent type II (TI-2), but not T cell-dependent (TD),
(Jumaa et al., 1999; Tan et al., 2001). BLNK can directly immune responses are defective in Bam32/ mice.
interact with PLC2 and is a key conduit for the PLC2 IgG3 is a main isotype generated in TI-2 immune re-
signaling branch (Niiro and Clark, 2002). sponses (Berland and Wortis, 2002), and without Bam32
Overview of Bam32 little or no IgG3 is generated to TI-2 antigens. This defect
The B lymphocyte adaptor molecule of 32 kDa (Bam32) makes Bam32/ mice highly vulnerable to infection with
adaptor, also called dual adaptor for phosphotyrosine an encapsulated bacteria, Streptococcus pneumoniae
and 3-phosphoinositides (DAPP1) or 3-phosphoinosi- (Fournier et al., 2003), because effective TI-2 responses
tide-interacting src homology-containing protein (PHISH), are needed to eradicate this bacteria (Berland and
is restricted to hematopoietic cells and expressed at
Wortis, 2002). In addition to peritoneal B-1a cells, MZ
high levels in germinal center (GC) B cells (Dowler et al.,
B cells have been implicated in TI-2 responses (Martin
et al., 2001). However, marginal zone B cells appear
normal in Bam32/ mice.*Correspondence: eclark@bart.rprc.washington.edu
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Figure 1. Overview of Bam32 (DAPP1/PHISH)
Impaired BCR-Induced Proliferation in Bam32/ in the Bam32/ DT40 B cells (Niiro et al., 2002), they
found that BCR-mediated activation of the JNK and ERKB Cells
What then might account for the inability of Bam32/ pathways is impaired in Bam32-deficient mouse B cells.
Significantly, activation of more upstream kinases, he-mice to mount a TI-2 response? Both groups found that
BCR-induced proliferation is impaired in Bam32/ B matopoietic progenitor kinase (HPK1) and MEK kinase
1 (MEKK1), is also greatly reduced in the absence ofcells. On the other hand, CD40-, LPS-, RP105 (CD180)-,
CD38-, and CpG-induced proliferation of Bam32/ B Bam32. Furthermore, HPK1 and Bam32 were found to
coassociate in normal B cells. These results suggestcells is normal. Use of a suboptimal dose of anti-IgM
resulted in a more drastic block in BCR-induced prolifer- that Bam32 regulates a novel BCR-induced signaling
branch (Figure 2). Our own data suggest that this branchation. Thus, Bam32 is required for a BCR-induced prolif-
eration of mature B cells but not for proliferation through of BCR signaling, unlike Akt activation, requires internal-
ization of the BCR (unpublished data).other receptors like CD40 or Toll-like receptors (TLR).
Notably, both groups found that defective BCR- Carma1 and B Cell Development and Activation
Another adaptor protein CARD-MAGUK1 (Carma1) (alsoinduced proliferation in the knockout cells is rescued
by costimulation with either CD40 or IL-4. This suggests called CARD11 and Bimp3), like Bam32, is relatively
restricted to the lymphoid compartment. In this casethat defective BCR signaling in Bam32/ cells is cor-
rected or bypassed by a downstream signal via CD40 the hallmarks are an N-terminal caspase recruitment
domain (CARD), a coiled-coil domain, and a C-terminalor IL-4. A remaining interesting question is whether B
cell activating factor of the tumor necrosis factor family guanylate kinase (GUK) domain. CARD-containing pro-
teins interact with each other via CARD-CARD binding.(BAFF/BLyS) can also rescue the defective BCR re-
sponse in Bam32/ B cells. BAFF is required for the When Carma1 is overexpressed, it can bind to another
CARD-containing protein Bcl10 and induce phosphory-generation of FO and MZ B cells, but not peritoneal B-
1a cells (Niiro and Clark, 2002). So one would expect lation of Bcl10 (Bertin et al., 2001). Since Bcl10 activates
I-B kinase (IKK) and is required for antigen receptor-that BAFF too can rescue BCR responses in Bam32/
B cells and thereby contribute to the normal generation induced activation of NF-B (Ruland et al., 2001), these
results suggested Carma1 may regulate activation ofof FO and MZ B cells in Bam32/ mice.
A decrease in cell survival or an increase in apoptosis NF-B through its interaction with Bcl10. This turns out
to be the case both for TCR- and BCR-induced activa-theoretically could contribute to a lower proliferative
capacity in Bam32/ B cells. Indeed, we previously tion of NF-B. T and B cells from mice missing either
all of Carma1 (Egawa et al., 2003; Hara et al., 2003), thefound that Bam32/ DT40 cells are more susceptible
to BCR-induced death (Niiro et al., 2002). However, Han CARD domain of Carma1 (Newton and Dixit, 2003), or
with a point mutation in the coiled-coil domain ofet al. found that Bam32/ mouse B cells survive nor-
mally after BCR crosslinking. This difference may be Carma1 (Jun et al., 2003) cannot be activated via their
antigen receptors to activate NF-B or recruit Bcl10 intodue to the fact that the DT40 cells, unlike the mouse B
cells, are cycling, and thus more susceptible to BCR- lipid rafts. Apparently, Carma1 is necessary to recruit
Bcl10 to lipid rafts where it is phosphorylated and byinduced cell death.
Basis of BCR Signaling Defect in Bam32/ B Cells some unknown mechanism in turn activates IKK. Since
PKC- is essential for BCR-induced activation of NF-While Fournier et al. (2003) did not uncover a BCR signal-
ing defect in Bam32/ B cells, Han et al. (2003) did. As B (Niiro and Clark, 2002), it is likely to phosphorylate
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upstream BCR signals into specific downstream signal-
ing branches (Figure 2). As mentioned earlier, BLNK
connects Syk and Btk signals into a downstream PLC2
pathway. In addition, BLNK is required for BCR-induced
activation of HPK1, while PLC2 is not (Liou et al., 2000).
This clearly suggests that the HPK1 pathway is both
PKC and Ca2 independent. Thus, BLNK regulates BCR-
induced activation of both HPK1 and PLC2. On the
other hand, Bam32 connects Lyn and Syk signals into
a downstream HPK1 pathway, but not directly to the
PLC2 pathway. Activation of HPK1 in turn leads to
MEKK1 activation that is required for BCR-induced acti-
vation of ERK and JNK, but not NF-B. In fact, PLC2
can also activate the ERK pathway via activation of Raf
family proteins (Brummer et al., 2002; Niiro and Clark,
2002). Consistent with normal activation of PLC2, Raf-1
activation is normal in mouse Bam32/ cells (Han et
al., 2003). In contrast to Bam32, Carma1 functions down-
stream of PLC2 (Figure 2). It connects PLC2 signals
into downstream pathways that eventually lead to BCR-
induced activation of JNK and NF-B, but not ERK.
What signals are then required for B cell survival? NF-
B activation is essential for survival of all mature B cell
subsets (peritoneal B-1a, FO, MZ) (Niiro and Clark, 2002).
One means by which NF-B supports B cell survival
would be the induction of antiapoptotic Bcl-2 family
members such as Bcl-xL, Bcl-2, and A1 (Niiro and Clark,
2002) and downregulation of proapoptotic BH3-only
Bcl-2 family members (Graves et al., 2003). It is thus of
interest to test the expression of Bcl-xL, Bcl-2, and A1
and other Bcl-2 family members in Bam32/ and
Carma1/ B cells.
How about the signals for B cell proliferation? Block-
Figure 2. Regulation of BCR Signaling Pathways by B Cell Conduits ade of the ERK pathway inhibits BCR-induced prolifera-
tion, but not cell survival in mature B cells (Niiro and
Clark, 2002). In addition, BCR-induced ERK activation
and regulate Carma1 and IKK in lipid rafts. In addition
is required for the induction of cyclin D family proteins
to NF-B activation, Carma1/ mice revealed that this
which are critical for cell cycle progression in B cells.
adaptor is also required for BCR-induced activation of
Intriguingly, disruption of cyclin D2 in B cells resulted in
JNK, but not ERK, although the molecular mechanism
impaired BCR-induced proliferation and defective B-1a
for this remains elusive (Hara et al., 2003; Jun et al., cell generation (Solvason et al., 2000), as similarly seen
2003). in Bam32/ mice. It is thus of interest to see the induc-
The findings with Carma1/ mice have been reviewed tion of cell cycle-related proteins including cyclin D2 in
recently (Abbas and Sen, 2003). However, it is of interest Bam32/ and Carma1/ B cells. How about the JNK
to compare the similarities and differences between B pathway? Although a role for this pathway in the function
cells missing either Bam32 or Carma1. First, B cell num- of mature B cells remain largely elusive, it may also
bers are relatively normal in both Bam32/ and regulate BCR-induced proliferation. Several studies in-
Carma1/ mice, except that peritoneal B-1a cells are cluding a recent one (Lamb et al., 2003) underscore that
greatly diminished (Egawa et al., 2003; Han et al., 2003; the JNK signaling branch in some contexts can promote
Jun et al., 2003; Newton and Dixit, 2003). Second, while cell survival.
both Bam32/ and Carma1/ B cells have defective Unanswered Questions
BCR-induced proliferation, Carma1/ B cells, unlike As we mentioned earlier, the mechanism by which
Bam32/ B cells, also have defective responses to Carma1 activates the NF-B pathway is relatively well
CD40 ligation and to LPS (Egawa et al., 2003; Hara et studied; how this adaptor activates the JNK pathway
al., 2003; Newton and Dixit, 2003). Thus, as might be is unclear. One intriguing question is which MAP3K is
expected, the Carma1/ mice not only have defective involved in this process. Since Carma1 does not affect
antibody responses to TI-2 antigens but also impaired the ERK pathway, another MAP3K other than MEKK1 is
responses to TD antigens. Third, an intriguing similarity most likely. Alternatively, Carma1 may directly connect
between Bam32/ and Carma1/ mice is that both MKK4/7 to a path that leads to JNK activation.
have defects in BCR-induced activation of JNK (Han et Although it is intriguing that Bam32 in particular regu-
al., 2003; Hara et al., 2003; Jun et al., 2003). lates the HPK1/MEKK1-dependent pathway, there are
Regulation of B Cell Signaling Branches yet-to-be-answered questions about this pathway. First,
by B Cell Conduits the downstream target for HPK1 is still not clear in B
Based on the findings above, it appears that B cells cells. Indeed, HPK1 is implicated in BCR-induced activa-
tion of NF-B in DT40 cells (Tsuji et al., 2001). This mayutilize certain adaptors as molecular conduits to channel
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Egawa, T., Albrecht, B., Favier, B., Sunshine, M.J., Mirchandani,be a good explanation for why there is a partial block
K., O’Brien, W., Thome, M., and Littman, D.R. (2003). Curr. Biol.in NF-B activation in Bam32/ DT40 cells (Niiro et al.,
13, 1252–1258.2002). The role of HPK1 in downstream BCR signaling
Fournier, E., Isakoff, S.J., Ko, K., Cardinale, C.J., Inghirami, G.G., Li,may differ between primary resting B cells and B cell
Z., Curotto de Lafaille, M.A., and Skolnik, E.Y. (2003). Curr. Biol.
lines or B cells in cycle. Second, HPK1 activation is 13, 1858–1866.
partially blocked, while MEKK1 activation is significantly Graves, J.D., Craxton, A., and Clark, E.A. (2003). Immunol. Rev.,
blocked in Bam32/ B cells. Thus, Bam32 may regulate in press.
MEKK1 activation in a HPK1-independent fashion. One Han, A., Saijo, K., Mecklenbrauker, I., Tarakhovsky, A., and Nussen-
interesting possibility is that Bam32 directly regulates zweig, M.C. (2003). Immunity 19, 621–632.
MEKK1 activation because both molecules possess PH Hara, H., Wada, T., Bakal, C., Kozieradzki, I., Suzuki, S., Suzuki, N.,
domains and thus may localize in the proximity of BCR Nghiem, M., Griffiths, E.K., Krawczyk, C., Bauer, B., et al. (2003).
Immunity 18, 763–775.complexes. Third, although MEKK1 is implicated in acti-
Jumaa, H., Wollscheid, B., Mitterer, M., Wienands, J., Reth, M., andvation of ERK and JNK (Yujiri et al., 1998), MEKK1/
Nielsen, P.J. (1999). Immunity 11, 547–554.DT40 cells have normal BCR-induced JNK activation
Jun, J.E., Wilson, L.E., Vinuesa, C.G., Lesage, S., Blery, M., Miosge,(Kwan et al., 2001). This may be due to the redundant
L.A., Cook, M.C., Kucharska, E.M., Hara, H., Penninger, J.M., et al.function of other MEKK isoforms such as MEKK2, 3,
(2003). Immunity 18, 751–762.and 4. If so, Bam32 may regulate activation of other
Kwan, R., Burnside, J., Kurosaki, T., and Cheng, G. (2001). Mol. Cell.MEKK isoforms as well. Fourth, Han et al. showed that
Biol. 21, 7183–7190.
BCR-induced activation of MEKK1 paralleled JNK acti-
Lam, K.P., Kuhn, R., and Rajewsky, K. (1997). Cell 90, 1073–1083.
vation, suggesting that MEKK1 regulates BCR-induced
Lamb, J.A., Ventura, J.J., Hess, P., Flavell, R.A., and Davis, R.J.JNK activation. By contrast, BCR-induced activation of
(2003). Mol. Cell 11, 1479–1489.
ERK and MEK1/2 peaked earlier than MEKK1 activation,
Liou, J., Kiefer, F., Dang, A., Hashimoto, A., Cobb, M.H., Kurosaki,
suggesting that MEKK1 may regulate the later phase of T., and Weiss, A. (2000). Immunity 12, 399–408.
ERK activation in B cells. If so, Bam32 may have another Marshall, A.J., Niiro, H., Lerner, C.G., Yun, T.J., Thomas, S., Disteche,
means to regulate an early phase of ERK activation. C.M., and Clark, E.A. (2000). J. Exp. Med. 191, 1319–1332.
It should be noted that a number of PH domain-con- Martin, F., Oliver, A.M., and Kearney, J.F. (2001). Immunity 14,
taining signaling molecules are often implicated in the 617–629.
process of actin reorganization. Preliminary work indi- Newton, K., and Dixit, V.M. (2003). Curr. Biol. 13, 1247–1251.
cates that Bam32 may indeed form tight caps with BCR Niiro, H., and Clark, E.A. (2002). Nat. Rev. Immunol. 2, 945–956.
and filamentous actin in B cells (unpublished data). In- Niiro, H., Maeda, A., Kurosaki, T., and Clark, E.A. (2002). J. Exp.
triguingly, MEKK1 is also tightly associated with actin Med. 195, 143–149.
fibers in cells (Cuevas et al., 2003). These findings raise Rao, V.R., Corradetti, M.N., Chen, J., Peng, J., Yuan, J., Prestwich,
the possibility that Bam32 may regulate actin-related G.D., and Brugge, J.S. (1999). J. Biol. Chem. 274, 37893–37900.
pathways in B cells. So, untangling all the roles of this Ruland, J., Duncan, G.S., Elia, A., del Barco Barrantes, I., Nguyen,
L., Plyte, S., Millar, D.G., Bouchard, D., Wakeham, A., Ohashi, P.S.,adaptor in B cells awaits further investigation.
and Mak, T.W. (2001). Cell 104, 33–42.In conclusion, we again stress that although the MAPK
Solvason, N., Wu, W.W., Parry, D., Mahony, D., Lam, E.W., Glassford,pathways are similarly activated in various cell types, B
J., Klaus, G.G., Sicinski, P., Weinberg, R., Liu, Y.J., et al. (2000). Int.cells utilize a unique machinery to trigger these path-
Immunol. 12, 631–638.ways. The studies of Bam32/ and Carma1/ mice
Tan, J.E., Wong, S.C., Gan, S.K., Xu, S., and Lam, K.P. (2001). J.clearly suggest that B cell adaptors play a critical role
Biol. Chem. 276, 20055–20063.
in this process. Further understanding of the mecha-
Tsuji, S., Okamoto, M., Yamada, K., Okamoto, N., Goitsuka, R.,
nisms by which these B cell adaptors function may lead Arnold, R., Kiefer, F., and Kitamura, D. (2001). J. Exp. Med. 194,
to therapeutic strategies which manipulate signaling 529–539.
pathways and alter B cell survival. Yujiri, T., Sather, S., Fanger, G.R., and Johnson, G.L. (1998). Science
282, 1911–1914.
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